Rit, a component of the Pola‐R‐CHP regimen, has an immune‐related mechanism of action targeting B lymphoma cells through processes such as ADCC/ADCP, whereby MΦs or NK cells bind to the antibody‐coated cancer cells [25]. The gene discussed is POLA1; the disease is cancer.